Self-adhesive label materials manufacturer UPM Raflatac is planning to present its labeling solutions designed for the latest pharmaceutical and healthcare market needs at the Pharmapack 2018 exhibition scheduled to be held in Paris, France.
At the event, which will take place from 7-8 February 2018, UPM Raflatac intends to showcase its labeling range which complies with the Falsified Medicines Directive (2011/62/EU) regarding packaging for prescription drugs and high-risk, over-the-counter medicines.
The firm will highlight its RP62 EU and RP62 EUL adhesives, which are supplied with tamper-verification labeling products.
Available with a range of clear film as well as paper-based label faces, the two adhesives support legislative requirements for individually authenticated, tamper-evident packs.
Other products to be showcased by the company at the event include RPMD adhesive range which is designed for medical device sub-segments such as sterilization wraps and bags, infusion bags and bottles, drug-device combinations like pens, auto-injectors and inhalers and blood donation labeling.
UPM said that the new multi-faceted RPMD adhesive, when combined with selected paper and film face materials, offer enhanced adhesion with a tight mandrel hold on glass and plastic.
Fully compliant with the recent EU Medical Devices and In Vitro Diagnostic Regulations, the RPMD adhesives are both sterilization resistant and migration safe.
In January 2018, UPM Raflatac has launched a new labelstock slitting and distribution terminal in Santiago, Chile to serve wine and craft beverage market.
The new terminal is intended to provide an expanded range of advanced and sustainable paper, film and specials products to the customers in the Chilean and surrounding markets such as Argentina, Bolivia, Paraguay and Peru.